The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

This study is testing a type of immune cell therapy — using donor gamma delta T cells — to treat patients with acute myeloid leukemia (AML) who still have traces of cancer in their blood or bone marrow (called MRD, or measurable residual disease) after a stem cell transplant. **You may be eligible if...** - You are 18 or older - You have been diagnosed with AML (based on standard classification criteria) - You have received an allogeneic (donor) stem cell transplant - Your risk level is considered favorable to intermediate - Tests show small amounts of remaining cancer (MRD-positive) - Your graft-versus-host disease (immune reaction to the transplant) is not currently active - Your blood counts and organ function are adequate **You may NOT be eligible if...** - Your leukemia has come back (5% or more blasts in blood or bone marrow) - You have active graft-versus-host disease - You have active HIV, hepatitis B or C, CMV, or EBV infections - You have unstable heart disease or a recent heart attack - You have other active cancers - You participated in another clinical study in the past 30 days Talk to your doctor to see if this trial is right for you.